RT Journal Article
T1 Beta-arrestins in the treatment of heart failure related to hypertension: a comprehensive review
A1 Rakib, Ahmed
A1 Eva, Taslima Akter
A1 Sami, Saad Ahmed
A1 Mitra, Saikat
A1 Nafiz, Iqbal Hossain
A1 Das, Ayan
A1 Tareq, Abu Montakim
A1 Nainu, Firzan
A1 Dhama, Kuldeep
A1 Emran, Talha Bin
A1 Simal Gándara, Jesús
K1 3207.04 Patología Cardiovascular
K1 3209 Farmacología
K1 3212 Salud Publica
AB Heart failure (HF) is a complicated clinical syndrome that is considered an increasingly frequent reason for hospitalization, characterized by a complex therapeutic regimen, reduced quality of life, and high morbidity. Long-standing hypertension ultimately paves the way for HF. Recently, there have been improvements in the treatment of hypertension and overall management not limited to only conventional medications, but several novel pathways and their pharmacological alteration are also conducive to the treatment of hypertension. Beta-arrestin (β-arrestin), a protein responsible for beta-adrenergic receptors’ (β-AR) functioning and trafficking, has recently been discovered as a potential regulator in hypertension. β-arrestin isoforms, namely β-arrestin1 and β-arrestin2, mainly regulate cardiac function. However, there have been some controversies regarding the function of the two β-arrestins in hypertension regarding HF. In the present review, we try to figure out the paradox between the roles of two isoforms of β-arrestin in the treatment of HF.
PB Pharmaceutics
SN 19994923
YR 2021
FD 2021-06-05
LK http://hdl.handle.net/11093/2515
UL http://hdl.handle.net/11093/2515
LA eng
NO Pharmaceutics, 13(6): 838 (2021)
DS Investigo
RD 25-ene-2025